Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

1.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups.

J Antimicrob Chemother. 2015 Jul;70(7):2084-9. doi: 10.1093/jac/dkv049. Epub 2015 Feb 26.

PMID:
25885327
2.

The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients.

Guidicelli G, Anies G, Bachelet T, Dubois V, Moreau JF, Merville P, Couzi L, Taupin JL.

Transpl Immunol. 2013 Dec;29(1-4):17-21. doi: 10.1016/j.trim.2013.09.005. Epub 2013 Sep 20.

PMID:
24056164
3.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Nov;68(11):2626-31. doi: 10.1093/jac/dkt238. Epub 2013 Jun 24.

4.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
5.

Molecular characterization of HIV-1 CRF01_AE in Mekong Delta, Vietnam, and impact of T-cell epitope mutations on HLA recognition (ANRS 12159).

Lazaro E, Tram LT, Bellecave P, Guidicelli GL, Anies G, Thu HH, Debelleix MP, Vray M, Recordon-Pinson P, Taupin JL, Lien TT, Fleury H.

PLoS One. 2011;6(10):e26244. doi: 10.1371/journal.pone.0026244. Epub 2011 Oct 19.

6.

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.

Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2010 Dec;65(12):2620-7. doi: 10.1093/jac/dkq380. Epub 2010 Oct 21.

7.

The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, Parissi V, Fleury H, Andreola ML.

PLoS One. 2010 Apr 26;5(4):e10311. doi: 10.1371/journal.pone.0010311.

8.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B.

J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12.

9.

Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.

Reigadas S, Andréola ML, Wittkop L, Cosnefroy O, Anies G, Recordon-Pinson P, Thiébaut R, Masquelier B, Fleury H.

J Antimicrob Chemother. 2010 Mar;65(3):434-7. doi: 10.1093/jac/dkp473. Epub 2010 Jan 5.

10.

Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9.

11.

HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity.

Recordon-Pinson P, Anies G, Bruyand M, Neau D, Morlat P, Pellegrin JL, Groppi A, Thiébaut R, Dabis F, Fleury H, Masquelier B; ANRS CO3 Aquitaine Cohort.

Antivir Ther. 2009;14(4):551-6.

PMID:
19578240
12.

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort.

J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31.

13.

Nonadherent cells switch to a Rac-mediated, SHIP regulated, Akt activation mode for survival.

Chaigne-Delalande B, Anies G, Kramer I, Genot E.

Oncogene. 2008 Mar 20;27(13):1876-85. Epub 2007 Oct 1.

PMID:
17906692
14.

Cdc42-driven podosome formation in endothelial cells.

Moreau V, Tatin F, Varon C, Anies G, Savona-Baron C, Génot E.

Eur J Cell Biol. 2006 Apr;85(3-4):319-25. Epub 2005 Oct 10.

PMID:
16546575
15.

RhoGTPases and p53 are involved in the morphological appearance and interferon-alpha response of hairy cells.

Chaigne-Delalande B, Deuve L, Reuzeau E, Basoni C, Lafarge D, Varon C, Tatin F, Anies G, Garand R, Kramer I, Génot E.

Am J Pathol. 2006 Feb;168(2):562-73.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk